Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y6X6
UPID:
MYO16_HUMAN
Alternative names:
Neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adapter 3; Unconventional myosin-16
Alternative UPACC:
Q9Y6X6; A6H8Y0; A8MTX3; Q5VYX4; Q5VYX5; Q5VYX6; Q6ZS13; Q8N3C2; Q8N948
Background:
Unconventional myosin-XVI, also known as Neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adapter 3, plays a crucial role in intracellular movements through its ATPase activity. It is involved in the targeting of protein phosphatase 1's catalytic subunit during brain development and activates PI3K, recruiting the WAVE1 complex to regulate neuronal morphogenesis.
Therapeutic significance:
Understanding the role of Unconventional myosin-XVI could open doors to potential therapeutic strategies.